Pfizer (PFE) announced that the European Commission has issued a decision amending the marketing authorization for Abrysvo, the company’s bivalent respiratory syncytial virus prefusion F vaccine, to extend the indication to include prevention of lower respiratory tract disease caused by RSV in individuals 18 through 59 years of age, expanding the previous authorization for individuals aged 60 and older.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer, Flagship Pioneerig partner for discovery of novel autoimmune compounds
- Pfizer announces European Commission approval of Abrysvo indication extension
- Pfizer’s Strategic Adaptation to Part D Redesign Drives Buy Rating
- Pfizer’s Strong Financial Performance and Strategic Developments Drive Buy Rating
- Hold Rating Maintained for Pfizer Amid Revenue Concerns and Limited Catalysts
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue